Axon Enterprise (NASDAQ:AXON) CEO Patrick Smith Sells 10,000 Shares of Stock

Axon Enterprise, Inc (NASDAQ:AXON) CEO Patrick Smith sold 10,000 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $619.01, for a total value of $6,190,100.00. Following the sale, the chief executive officer owned 3,100,997 shares in the company, valued at $1,919,548,152.97. This trade represents a 0.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Axon Enterprise Stock Down 1.3%

AXON opened at $612.98 on Friday. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The business has a 50-day moving average of $574.87 and a two-hundred day moving average of $689.86. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. The stock has a market capitalization of $48.37 billion, a price-to-earnings ratio of 193.98, a price-to-earnings-growth ratio of 19.55 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). The company had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.Axon Enterprise’s revenue was up 30.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.45 earnings per share. On average, research analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in shares of Axon Enterprise during the fourth quarter worth about $480,000. NewEdge Advisors LLC increased its holdings in Axon Enterprise by 41.1% during the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after purchasing an additional 668 shares during the last quarter. Signature Estate & Investment Advisors LLC increased its holdings in Axon Enterprise by 4.3% during the 1st quarter. Signature Estate & Investment Advisors LLC now owns 532 shares of the biotechnology company’s stock worth $280,000 after purchasing an additional 22 shares during the last quarter. MBB Public Markets I LLC acquired a new position in shares of Axon Enterprise in the 1st quarter valued at approximately $294,000. Finally, Empowered Funds LLC boosted its stake in shares of Axon Enterprise by 8.4% during the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after buying an additional 157 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AXON shares. Needham & Company LLC reissued a “buy” rating and set a $870.00 price target on shares of Axon Enterprise in a research report on Wednesday, September 24th. Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a report on Tuesday. Wall Street Zen lowered shares of Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. Finally, JMP Securities reissued a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus price target of $805.71.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.